FIS Implements New Board Leadership Structure to Drive Enhanced Shareholder Value; Stephanie L. Ferris Assumes CEO Role

Jeffrey A. Goldstein to Become Independent Chairman of the Board of Directors, Effective December 16, 2022

Gary A. Norcross, a Dedicated Member of the FIS Team for Over 34 Years, to Depart from Company and Board

FIS^® (NYSE: FIS), a global leader in financial services technology, today announced updates to its Board of Directors and leadership team to drive enhanced shareholder value. Consistent with the Board's focus on enhancing corporate governance, FIS will transition to an independent Board Chair structure. Jeffrey A. Goldstein, Lead Independent Director of the FIS Board, has been appointed as Independent Chairman, effective December 16, 2022. In conjunction with this appointment, Stephanie L. Ferris, previously announced as incoming Chief Executive Officer, will succeed Gary A. Norcross effective December 16, 2022. As part of the leadership transition of the Board, Mr. Norcross will depart from the Board of FIS on the same date.

"FIS is well positioned for growth across our markets and we are moving forward with this new Board leadership structure from a position of great opportunity," said Mr. Goldstein, Lead Independent Director of the FIS Board and incoming Independent Chairman of the Board. "Stephanie is an accomplished industry veteran with expertise in payments, technology platform businesses and driving transformation and has already demonstrated at FIS how she will leverage her deep understanding of FIS' colleagues, clients and strategy to lead the organization with her reputation for driving operational excellence, disciplined innovation and client inspiration. The Board is confident she is the ideal leader to take the Company forward and enhance shareholder value."

Mr. Goldstein concluded: "We are grateful to Gary for his over 34 years of dedicated service and many important contributions to FIS. Gary provided tremendous leadership in his varying roles at FIS over the years, overseeing the expansion of FIS' product portfolio and global footprint and setting the strategy for the Company to become indispensable to our clients. He was also a strong mentor to our colleagues and has been committed to continually identifying, growing, recruiting and developing FIS talent. On behalf of the entire Board, I thank Gary for his unwavering commitment. He and Stephanie have worked to ensure a seamless transition for our clients, colleagues, shareholders and partners."

In her role as FIS President, Ms. Ferris has been responsible for steering and executing the Company's global business strategy, including M&A, and its global business operations serving financial institutions, merchants and corporates of all sizes and geographies. A 28-year industry veteran with expertise in payments, technology platform businesses and driving digital transformation, Ms. Ferris has been integral to FIS' growth globally, where it currently supports more than 20,000 businesses and over a million merchant locations.

"I am honored to serve as CEO of FIS during such an important and exciting phase in the Company and our industry," said Ms. Ferris. "My time as President has reinforced what a talented global team we have, and I look forward to leading this organization as we build on our momentum and continue to create value for our clients, partners, colleagues and shareholders. FIS' stellar history, marquee clients and successful innovation provide an unrivaled foundation for us to chart FIS' future course for fintech innovation and value creation, and I'm incredibly excited to lead the company into its future."

"It has been a privilege to serve as CEO of FIS and I am proud of all that we have accomplished during my tenure," said Mr. Norcross. "Stephanie's previously announced appointment has been part of a thoughtful succession plan and I am confident that she is the right person to lead FIS into its next phase of value creation. The Board and I believe now is the right time to transition to an independent Board Chair structure, and we are confident that Jeffrey is the right person to lead this transition."

In addition, as separately announced, FIS is initiating a comprehensive assessment of the Company's strategy, businesses, operations and structure with the goal of positioning the Company to drive stronger results, increase shareholder value and enhance client services. Further, following the Board's appointment of two new independent directors earlier this year, the Board has appointed a new, highly qualified independent director to the Board. That press release can be found at www.investor.fisglobal.com/press-releases .

About Jeffrey A. Goldstein

Mr. Goldstein is a Senior Advisor to Canapi Ventures, a fintech-oriented venture capital firm, and Advisor Emeritus at Hellman & Friedman LLC, one of the oldest and most experienced private equity investment firms. Mr. Goldstein has extensive experience in mergers and acquisitions, corporate finance and government and financial regulation. Previously, Mr. Goldstein was a Managing Director and Senior Advisor at Hellman & Friedman. From 2009 to 2011, he served as the Under Secretary of the Treasury for Domestic Finance and Counselor to the Secretary of the Treasury. Mr. Goldstein was a Managing Director of the World Bank, where he also served as the Chief Financial Officer. He was also the Co-Chairman of the investment bank BT Wolfensohn and a partner at its predecessor organizations. Since 2014, Mr. Goldstein has served as a Board member of Bank of New York Mellon. Mr. Goldstein earned a Bachelor of Arts degree from Vassar College and a Master of Arts, Master of Philosophy and a Ph.D. in economics from Yale University.

About FIS

FIS is a leading provider of technology solutions for financial institutions and businesses of all sizes and across any industry globally. We enable the movement of commerce by unlocking the financial technology that powers the world's economy. Our employees are dedicated to advancing the way the world pays, banks and invests through our trusted innovation, system performance and flexible architecture. We help our clients use technology in innovative ways to solve business-critical challenges and deliver superior experiences for their customers. Headquartered in Jacksonville, Florida, FIS is a member of the Fortune 500 ^® and the Standard & Poor's 500 ^® Index. To learn more, visit www.fisglobal.com . Follow FIS on Facebook , LinkedIn and Twitter ( @FISGlobal ).

Forward Looking Statements

This release contains "forward-looking statements" within the meaning of the U.S. federal securities laws. Statements that are not historical facts, including statements about anticipated financial outcomes, including any earnings guidance or projections of the Company, projected revenue or expense synergies, business and market conditions, outlook, foreign currency exchange rates, deleveraging plans, expected dividends and share repurchases, the Company's sales pipeline and anticipated profitability and growth, the outcome of our comprehensive assessment referred to in this release, as well as other statements about our expectations, beliefs, intentions, or strategies regarding the future, or other characterizations of future events or circumstances, are forward-looking statements. These statements may be identified by words such as "expect," "anticipate," "intend," "plan," "believe," "will," "should," "could," "would," "project," "continue," "likely," and similar expressions, and include statements reflecting future results or guidance, statements of outlook and various accruals and estimates. These statements relate to future events and our future results and involve a number of risks and uncertainties. Forward-looking statements are based on management's beliefs as well as assumptions made by, and information currently available to, management.

Actual results, performance or achievement could differ materially from those contained in these forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include the following, without limitation:

changes in general economic, business and political conditions, including those resulting from COVID-19 or other pandemics, a recession, intensified international hostilities, acts of terrorism, increased rates of inflation or interest, changes in either or both the United States and international lending, capital and financial markets or currency fluctuations;
the outbreak or recurrence of the novel coronavirus and any related variants ("COVID-19") and measures to reduce its spread, including the impact of governmental or voluntary actions such as business shutdowns and stay-at-home orders in certain geographies;
the duration, including any recurrence, of the COVID-19 pandemic and its impacts, including reductions in consumer and business spending, and instability of the financial markets in heavily impacted areas across the globe;
the economic and other impacts of COVID-19 on our clients which affect the sales of our solutions and services and the implementation of such solutions;
the risk of losses in the event of defaults by merchants (or other parties) to which we extend credit in our card settlement operations or in respect of any chargeback liability, either of which could adversely impact liquidity and results of operations;
the risk that acquired businesses will not be integrated successfully or that the integration will be more costly or more time-consuming and complex than anticipated;
the risk that cost savings and synergies anticipated to be realized from acquisitions may not be fully realized or may take longer to realize than expected;
the risks of doing business internationally;
the effect of legislative initiatives or proposals, statutory changes, governmental or applicable regulations and/or changes in industry requirements, including privacy and cybersecurity laws and regulations;
the risks of reduction in revenue from the elimination of existing and potential customers due to consolidation in, or new laws or regulations affecting, the banking, retail and financial services industries or due to financial failures or other setbacks suffered by firms in those industries;
changes in the growth rates of the markets for our solutions;
the amount, declaration and payment of future dividends is at the discretion of our Board of Directors and depends on, among other things, our investment opportunities, results of operations, financial condition, cash requirements, future prospects, the duration and impact of the COVID-19 pandemic, and other factors that may be considered relevant by our Board of Directors, including legal and contractual restrictions;
the amount and timing of any future share repurchases is subject to, among other things, our share price, our other investment opportunities and cash requirements, our results of operations and financial condition, our future prospects and other factors that may be considered relevant by our Board of Directors and management;
failures to adapt our solutions to changes in technology or in the marketplace;
internal or external security breaches of our systems, including those relating to unauthorized access, theft, corruption or loss of personal information and computer viruses and other malware affecting our software or platforms, and the reactions of customers, card associations, government regulators and others to any such events;
the risk that implementation of software, including software updates, for customers or at customer locations or employee error in monitoring our software and platforms may result in the corruption or loss of data or customer information, interruption of business operations, outages, exposure to liability claims or loss of customers;
the reaction of current and potential customers to communications from us or regulators regarding information security, risk management, internal audit or other matters;
the risk that policies and resulting actions of the current administration in the U.S. may result in additional regulations and executive orders, as well as additional regulatory and tax costs;
competitive pressures on pricing related to the decreasing number of community banks in the U.S., the development of new disruptive technologies competing with one or more of our solutions, increasing presence of international competitors in the U.S. market and the entry into the market by global banks and global companies with respect to certain competitive solutions, each of which may have the impact of unbundling individual solutions from a comprehensive suite of solutions we provide to many of our customers;
the failure to innovate in order to keep up with new emerging technologies, which could impact our solutions and our ability to attract new, or retain existing, customers;
an operational or natural disaster at one of our major operations centers;
failure to comply with applicable requirements of payment networks or changes in those requirements;
fraud by merchants or bad actors; and
other risks detailed in the "Risk Factors" and other sections of our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, in our quarterly reports on Form 10-Q, in our current reports on Form 8-K and in our other filings with the Securities and Exchange Commission.

Other unknown or unpredictable factors also could have a material adverse effect on our business, financial condition, results of operations and prospects. Accordingly, readers should not place undue reliance on these forward-looking statements. These forward-looking statements are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict. Except as required by applicable law or regulation, we do not undertake (and expressly disclaim) any obligation and do not intend to publicly update or review any of these forward-looking statements, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221215005524/en/

Kim Snider
Senior Vice President
FIS Global Marketing and Corporate Communications
904.438.6278
kim.snider@fisglobal.com

George Mihalos
Senior Vice President
Head of Investor Relations
904.438.6119
georgios.mihalos@fisglobal.com

News Provided by Business Wire via QuoteMedia

Fidelity National Information Services FIS Fintech Investing

FIS

QIAGEN expands QIAstat-Dx syndromic testing menu in the U.S. with launch of molecular test to improve gastrointestinal care

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the QIAstat-Dx Gastrointestinal Panel 2 in the United States. The launch comes after the recent clearance of the syndromic test for clinical use by the U.S. Food and Drug Administration (FDA) and marks a significant step forward in improving the accuracy and efficiency of gastrointestinal (GI) infection diagnosis.

The QIAstat-Dx Gastrointestinal Panel 2 takes about an hour to simultaneously look for up to 16 clinically relevant bacterial, viral and parasitic pathogens that cause most GI infections. Acute infectious gastroenteritis is a common reason for hospitalizations and outpatient physician visits in the U.S., with an estimated 180 million cases per year. [1]

The panel leverages QIAstat-Dx's ability to quickly multiply many genetic targets using real-time PCR technology in the same reaction – an important advance compared to traditional microbiological testing, which often requires samples to be incubated for at least 24 hours and up to 10 days of specimen collection. Software interprets signals from the reaction and provides positive or negative results for each pathogen. QIAstat-Dx additionally provides easy-to-view cycle threshold (Ct) values and amplification curves that can offer additional insights not available with end-point PCR or other techniques.

"The QIAstat-Dx Gastrointestinal Panel 2 allows medical professionals to identify which GI pathogen they are dealing with quickly," said Fernando Beils, Senior Vice President and Head of the Molecular Diagnostics Business Area at QIAGEN. "This is QIAGEN's answer to two major problems in treating GI infections: diagnosis of overlapping symptoms and laborious testing methods."

"It can be very difficult to clinically distinguish between viral, bacterial and parasitic causes of GI illness. We can easily set up and get a full panel of results back faster than culture and microscopy, and access to Ct values for each detected pathogen can provide valuable information when interpreting when interpreting multiple pathogen detections," added Romney Humphries, Ph.D., professor of Pathology, Microbiology, and Immunology and division director for Laboratory Medicine at Vanderbilt University Medical Center in the U.S. about the clinical utility of QIAstat-Dx.

The new panel expands QIAGEN's U.S. menu for syndromic testing, building on the use of the QIAstat-Dx Respiratory Panel Plus that can identify 21 pathogens causing respiratory infections from viral and bacterial pathogens. Both Panels are available as cost-efficient, single-use cartridges that slot easily into the QIAstat-Dx Analyzer 1.0. As they contain all reagents, set up takes less than a minute and requires no precision pipetting.

The U.S. launch supports healthcare providers with diagnosing and treating patients quickly and accurately. They will be able to quickly isolate those at risk of transmitting infections and identify negative cases sooner, reducing the burden of unnecessary testing and treatment costs on the healthcare system and patients. Syndromic tests have also been shown to improve the detection of co-infections, reducing the need for additional testing like endoscopies. By providing fast results, syndromic testing enables healthcare providers to make informed decisions and discontinue empiric antibiotic treatment when viral pathogens are detected, reducing overall antibiotic usage and supporting the goal of responsible antimicrobial stewardship.

Syndromic testing with cloud-based connectivity and epidemiological insights

QIAstat-Dx solutions and syndromic tests to support diagnosing diseases are available in more than 100 countries worldwide, including the U.S. and many across Europe. More than 4,000 cumulative systems were installed worldwide at the end of 2023. Hospitals, laboratories and clinics value the QIAstat-Dx range as an easy-to-use automated solution for the reliable detection of various pathogens.

QIAstat-Dx is available in two formats: The QIAstat-Dx version that brings together up to four Analytical Modules into one integrated system, and the QIAstat-Dx Rise higher-capacity version that provides comprehensive testing for up to 160 tests per day using eight Analytical Modules. QIAstat-Dx Rise is available with CE-IVD marking in Europe and other countries that accept this marking.

With a QIAstat-Dx Connectivity plan, QIAstat-Dx connects to the QIAsphere cloud-based platform that provides remote monitoring of the instruments and test status, allowing customers to receive push notifications on their personal devices. It can monitor an unlimited number of instruments across different hospitals or satellite labs, reducing system downtime and enabling fast and accurate syndromic testing. Connectivity is achieved through the Qbase hub, which can be connected to QIAstat-Dx in minimal time through hospitals' LAN or Wi-Fi network, ensuring sensitive patient data remains within the hospital network.

QIAsphere also allows users to view and export reports on real-time local, regional and global epidemiology data through QIAsphere Insights to support epidemiological surveillance . Further, with the recent release of a medical reference app for QIAstat-Dx users, the Pathogen Guide , QIAstat-Dx is poised as a leader in digital diagnostic technology for customers around the world.

Learn more about QIAstat-Dx and the Gastrointestinal Panel 2 at https://www.qiagen.com/applications/syndromic-testing/benefits/gastrointestinal-care

About QIAGEN

Qiagen N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of March 31, 2024, QIAGEN employed approximately 5,900 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com .

Forward-Looking Statement

Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, including those products used in the response to the COVID-19 pandemic, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, collaborations, markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, weather or transportation delays, natural disasters, political or public health crises, including the breadth and duration of the COVID-19 pandemic and its impact on the demand for our products and other aspects of our business, or other force majeure events; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading "Risk Factors" contained in Item 3 of our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission.

Source: Qiagen N.V.
Category: Corporate

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Real Matters Announces Changes to its Board of Directors

Real Matters Inc. ("Real Matters" or the "Company"), a leading network management services provider for the mortgage lending and insurance industries, today announced that Lisa Melchior will be stepping down after serving on the Real Matters Board since 2017. The Company also announced the appointment of Kay Brekken to its Board of Directors. Ms. Brekken will succeed Ms. Melchior as a member of the Compensation, Nomination and Governance Committee. The changes are effective May 7, 2024.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240507719548/en/

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Real Matters to Hold Virtual Annual General Meeting on February 8, 2024

Real Matters Inc. ("Real Matters"), a leading network management services provider for the mortgage lending and insurance industries, will be holding its Annual General Meeting (the "Meeting") on Thursday, February 8, 2024 at 10:00 a.m. (Eastern Standard Time). The Meeting will be conducted online only, via audio webcast at: www.virtualshareholdermeeting.com/realmatters2024 .

Registered and non-registered shareholders entitled to vote at the Meeting may vote by proxy in advance of the Meeting. However, only registered shareholders and duly appointed proxyholders (including non-registered shareholders who have duly appointed themselves as proxyholder) will be entitled to vote at the Meeting during the live audio webcast. Non-registered shareholders who have not duly appointed themselves as proxyholders will be able to attend the Meeting and ask questions, but will not be able to vote. Guests will be able to attend the Meeting but will not be able to submit questions, vote their shares (if any) or otherwise participate in the Meeting. Please note that registered shareholders will need the 16-digit control number indicated on the form of proxy accompanying their Notice of Meeting to log on to the Meeting as a "Shareholder". Duly appointed proxyholders will need the Appointee Name and 8-character Appointee Identification Number to log on to the Meeting as a "Proxyholder / Appointee". Otherwise, shareholders or duly appointed proxyholders, as applicable, will have to log on as "Guests". Please refer to the Company's Management Information Circular in the Investor Relations section of our website for additional details on how to log on to the Meeting.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

(millions of dollars)		Quarter ended											Six months ended					%
		2024		2024		2023		2023		2023	% Change				2024		2023	Change
		Q2		Q1		Q4		Q3		Q2	Quarter over Quarter	Year over Year		March 31		March 31		Year over Year
Consolidated
Revenue	$	42.2	$	35.4	$	42.2	$	46.0	$	37.6	19%	12%		$	77.6	$	75.8	2%
Net Revenue ^(A)	$	11.5	$	9.7	$	11.2	$	12.1	$	9.9	19%	16%		$	21.2	$	19.7	8%
Adjusted EBITDA ^(A)	$	0.7	$	(1.1)	$	0.6	$	1.7	$	(1.7)	166%	142%		$	(0.4)	$	(4.6)	92%
Net income (loss)	$	2.1	$	(3.6)	$	1.6	$	(0.6)	$	(2.6)	158%	181%		$	(1.5)	$	(7.2)	79%
Net income (loss) per diluted share	$	0.03	$	(0.05)	$	0.02	$	(0.01)	$	(0.04)	160%	175%		$	(0.02)	$	(0.10)	80%
Adjusted Net income (loss) ^(A)	$	1.3	$	(1.2)	$	0.8	$	1.0	$	(1.9)	207%	168%		$	0.1	$	(4.0)	103%
Adjusted Net income (loss) ^(A) per diluted share	$	0.02	$	(0.02)	$	0.01	$	0.01	$	(0.03)	200%	167%		$	-	$	(0.06)	100%

U.S. Appraisal segment
Revenue	$	32.6	$	26.8	$	31.2	$	33.5	$	28.0	22%	16%		$	59.3	$	56.3	6%
Net Revenue ^(A)	$	9.2	$	7.5	$	8.6	$	9.2	$	7.7	23%	19%		$	16.6	$	15.4	9%
Net Revenue ^(A) margin		28.3%		27.9%		27.5%		27.5%		27.6%					28.1%		27.3%
Adjusted EBITDA ^(A)	$	4.4	$	2.7	$	3.9	$	4.8	$	3.1	65%	40%		$	7.1	$	5.5	30%
Adjusted EBITDA ^(A) margin		47.9%		35.8%		46.0%		52.0%		40.6%					42.5%		35.5%

U.S. Title segment
Revenue	$	2.0	$	2.0	$	2.3	$	2.6	$	2.2	0%	-9%		$	4.1	$	4.6	-11%
Net Revenue ^(A)	$	0.9	$	1.0	$	1.0	$	1.2	$	0.8	-7%	9%		$	1.9	$	1.6	13%
Net Revenue ^(A) margin		44.0%		47.3%		45.0%		45.2%		36.8%					45.7%		35.7%
Adjusted EBITDA ^(A)	$	(1.7)	$	(1.6)	$	(1.6)	$	(1.6)	$	(2.3)	-2%	28%		$	(3.3)	$	(5.2)	37%
Adjusted EBITDA ^(A) margin		-184.8%		-167.9%		-150.4%		-133.6%		-279.3%					-176.0%		-316.4%

Canadian segment
Revenue	$	7.6	$	6.6	$	8.7	$	9.9	$	7.4	15%	2%		$	14.2	$	14.9	-5%
Net Revenue ^(A)	$	1.4	$	1.2	$	1.6	$	1.7	$	1.4	15%	3%		$	2.7	$	2.7	-2%
Net Revenue ^(A) margin		18.9%		18.8%		17.9%		17.6%		18.7%					18.8%		18.3%
Adjusted EBITDA ^(A)	$	0.9	$	0.7	$	1.2	$	1.3	$	1.0	26%	-8%		$	1.6	$	1.8	-13%
Adjusted EBITDA ^(A) margin		62.3%		56.8%		72.9%		73.7%		69.8%					59.7%		67.0%

Corporate segment
Adjusted EBITDA ^(A)	$	(2.9)	$	(2.9)	$	(2.9)	$	(2.8)	$	(3.5)	-4%	16%		$	(5.8)	$	(6.7)	14%

						Quarter ended					Six months ended
		Q2 2024		Q1 2024		Q4 2023		Q3 2023		Q2 2023	March 31, 2024		March 31, 2023

Net income (loss)	$	2.1	$	(3.6)	$	1.6	$	(0.6)	$	(2.6)	$	(1.5)	$	(7.2)
Operating expenses		11.2		11.6		10.9		10.7		11.9		22.8		25.1
Amortization		0.8		0.8		0.9		1.0		1.0		1.6		2.0
Restructuring expenses		-		-		-		-		0.4		-		1.7
Interest expense		0.1		0.1		0.1		0.1		0.1		0.2		0.2
Interest income		(0.4)		(0.4)		(0.3)		(0.2)		(0.2)		(0.8)		(0.3)
Net foreign exchange (gain) loss		(2.2)		2.0		(1.8)		1.8		0.1		(0.2)		1.1
Loss (gain) on fair value of derivatives		0.1		(0.2)		(0.1)		(0.5)		(0.3)		(0.1)		(0.3)
Income tax recovery		(0.2)		(0.6)		(0.1)		(0.2)		(0.5)		(0.8)		(2.6)
Net Revenue	$	11.5	$	9.7	$	11.2	$	12.1	$	9.9	$	21.2	$	19.7

						Quarter ended					Six months ended
		Q2 2024		Q1 2024		Q4 2023		Q3 2023		Q2 2023	March 31, 2024		March 31, 2023

Net income (loss)	$	2.1	$	(3.6)	$	1.6	$	(0.6)	$	(2.6)	$	(1.5)	$	(7.2)
Stock-based compensation expense		0.4		0.8		0.3		0.3		0.3		1.2		0.8
Amortization		0.8		0.8		0.9		1.0		1.0		1.6		2.0
Restructuring expenses		-		-		-		-		0.4		-		1.7
Interest expense		0.1		0.1		0.1		0.1		0.1		0.2		0.2
Interest income		(0.4)		(0.4)		(0.3)		(0.2)		(0.2)		(0.8)		(0.3)
Net foreign exchange (gain) loss		(2.2)		2.0		(1.8)		1.8		0.1		(0.2)		1.1
Loss (gain) on fair value of derivatives		0.1		(0.2)		(0.1)		(0.5)		(0.3)		(0.1)		(0.3)
Income tax recovery		(0.2)		(0.6)		(0.1)		(0.2)		(0.5)		(0.8)		(2.6)
Adjusted EBITDA	$	0.7	$	(1.1)	$	0.6	$	1.7	$	(1.7)	$	(0.4)	$	(4.6)

						Quarter ended					Six months ended
		Q2 2024		Q1 2024		Q4 2023		Q3 2023		Q2 2023	March 31, 2024		March 31, 2023

Net income (loss)	$	2.1	$	(3.6)	$	1.6	$	(0.6)	$	(2.6)	$	(1.5)	$	(7.2)
Stock-based compensation expense		0.4		0.8		0.3		0.3		0.3		1.2		0.8
Amortization of intangibles		0.4		0.4		0.4		0.4		0.4		0.8		0.8
Restructuring expenses		-		-		-		-		0.4		-		1.7
Net foreign exchange (gain) loss		(2.2)		2.0		(1.8)		1.8		0.1		(0.2)		1.1
Loss (gain) on fair value of derivatives		0.1		(0.2)		(0.1)		(0.5)		(0.3)		(0.1)		(0.3)
Related tax effects		0.5		(0.6)		0.4		(0.4)		(0.2)		(0.1)		(0.9)
Adjusted Net Income (Loss)	$	1.3	$	(1.2)	$	0.8	$	1.0	$	(1.9)	$	0.1	$	(4.0)

(millions of dollars)		Quarter ended
		2024			2023			2023			2023			2023		% Change
		Q1			Q4			Q3			Q2			Q1		Quarter over Quarter		Year over Year
Consolidated
Revenue	$	35.4		$	42.2		$	46.0		$	37.6		$	38.2		-16	%	-7	%
Net Revenue ^(A)	$	9.7		$	11.2		$	12.1		$	9.9		$	9.8		-13	%	-1	%
Adjusted EBITDA ^(A)	$	(1.1	)	$	0.6		$	1.7		$	(1.7	)	$	(2.9	)	-280	%	64	%
Net (loss) income	$	(3.6	)	$	1.6		$	(0.6	)	$	(2.6	)	$	(4.6	)	-322	%	22	%
Net (loss) income per diluted share	$	(0.05	)	$	0.02		$	(0.01	)	$	(0.04	)	$	(0.06	)	-350	%	17	%
Adjusted Net (loss) income ^(A)	$	(1.2	)	$	0.8		$	1.0		$	(1.9	)	$	(2.1	)	-241	%	43	%
Adjusted Net (loss) income ^(A) per diluted share	$	(0.02	)	$	0.01		$	0.01		$	(0.03	)	$	(0.03	)	-300	%	33	%

U.S. Appraisal segment
Revenue	$	26.8		$	31.2		$	33.5		$	28.0		$	28.3		-14	%	-5	%
Net Revenue ^(A)	$	7.5		$	8.6		$	9.2		$	7.7		$	7.6		-13	%	-2	%
Net Revenue ^(A) margin		27.9	%		27.5	%		27.5	%		27.6	%		27.0	%
Adjusted EBITDA ^(A)	$	2.7		$	3.9		$	4.8		$	3.1		$	2.3		-32	%	16	%
Adjusted EBITDA ^(A) margin		35.8	%		46.0	%		52.0	%		40.6	%		30.4	%

U.S. Title segment
Revenue	$	2.0		$	2.3		$	2.6		$	2.2		$	2.4		-13	%	-14	%
Net Revenue ^(A)	$	1.0			1.0		$	1.2			0.8		$	0.8		-8	%	18	%
Net Revenue ^(A) margin		47.3	%		45.0	%		45.2	%		36.8	%		34.7	%
Adjusted EBITDA ^(A)	$	(1.6	)	$	(1.6	)	$	(1.6	)	$	(2.3	)	$	(2.9	)	-2	%	44	%
Adjusted EBITDA ^(A) margin		-167.9	%		-150.4	%		-133.6	%		-279.3	%		-353.4	%

Canadian segment
Revenue	$	6.6		$	8.7		$	9.9		$	7.4		$	7.5		-24	%	-12	%
Net Revenue ^(A)	$	1.2		$	1.6		$	1.7		$	1.4		$	1.4		-20	%	-8	%
Net Revenue ^(A) margin		18.8	%		17.9	%		17.6	%		18.7	%		17.9	%
Adjusted EBITDA ^(A)	$	0.7		$	1.2		$	1.3		$	1.0		$	0.9		-38	%	-19	%
Adjusted EBITDA ^(A) margin		56.8	%		72.9	%		73.7	%		69.8	%		64.2	%

Corporate segment
Adjusted EBITDA ^(A)	$	(2.9	)	$	(2.9	)	$	(2.8	)	$	(3.5	)	$	(3.2	)	2	%	9	%

								Quarter ended
		Q1 2024			Q4 2023			Q3 2023			Q2 2023			Q1 2023

Net (loss) income	$	(3.6	)	$	1.6		$	(0.6	)	$	(2.6	)	$	(4.6	)
Operating expenses		11.6			10.9			10.7			11.9			13.2
Amortization		0.8			0.9			1.0			1.0			1.0
Restructuring expenses		-			-			-			0.4			1.3
Interest expense		0.1			0.1			0.1			0.1			0.1
Interest income		(0.4	)		(0.3	)		(0.2	)		(0.2	)		(0.1	)
Net foreign exchange loss (gain)		2.0			(1.8	)		1.8			0.1			1.0
Gain on fair value of derivatives		(0.2	)		(0.1	)		(0.5	)		(0.3	)		-
Income tax recovery		(0.6	)		(0.1	)		(0.2	)		(0.5	)		(2.1	)
Net Revenue	$	9.7		$	11.2		$	12.1		$	9.9		$	9.8

FIS Implements New Board Leadership Structure to Drive Enhanced Shareholder Value; Stephanie L. Ferris Assumes CEO Role

Latest News

Latest Press Releases

Related News

TOP STOCKS